Cadrenal Therapeutics, Inc. Common Stock

NasdaqCM CVKD

Cadrenal Therapeutics, Inc. Common Stock Inventory for the quarter ending September 30, 2024

Cadrenal Therapeutics, Inc. Common Stock Inventory is NA for the quarter ending September 30, 2024. Inventory is the value of goods held by a company for sale or used in the production process.

Key data

Date	Inventory	Goodwill	Total Assets	Current Liabilities

NasdaqCM: CVKD

Cadrenal Therapeutics, Inc. Common Stock

CEO	Mr. Quang X. Pham
IPO Date	Jan. 20, 2023
Location	United States
Headquarters	822 A1A North
Employees	4
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Key trends

Past 5 years